Background and Aims: Intermediate stage hepatocellular carcinoma (HCC) can be treated by transarterial chemoembolization (TACE). However, there appear to be side effects, such as induction of proangiogenic factors, e.g. vascular endothelial growth factor (VEGF), which have been shown to be associated with a poor prognosis. This prospective study was designed to compare serum VEGF level response after TACE with different embolic agents in patients with HCC. Methods: Patients were assigned to one of three different TACE regimens: degradable starch microspheres (DSM) TACE, drug-eluting bead (DEBDOX) TACE or Lipiodol TACE (cTACE). All patients received 50 mg doxorubicin/m² body surface area (BSA) during TACE. Serum VEGF levels were assessed before TACE treatment, 24 h post-treatment and 4 weeks later. Results: Twenty-two patients with 30 TACE treatments were enrolled. Compared to baseline VEGF levels, a marked increase was observed for 24 h post-TACE (164% of baseline level) and during the 4-week follow-up (170% of baseline level) only for the cTACE arm (p < 0.05). In contrast, the increase of serum VEGF levels were only 114% and 123% for DEBDOX and 121% and 124% for DSM, respectively. Conclusions: Conventional TACE using Lipiodol shows marked increase in blood levels of the proangiogenic factor VEGF, while DEBDOX and DSM TACE induce only a moderate VEGF response.

OpenAI’s GPT-4V reliably identified the imaging modality and anatomic region but could not safely detect, classify, or rule out abnormalities on single MRI, CT, and radiographic images.

Although high mortality rates have been reported for emphysematous pyelonephritis (EP), information on emphysematous cystitis (EC), which is less common, is sparse. Here, we report one new case of severe EC and 136 cases of EC that occurred between 2007 and 2016, and review information about the characteristics, diagnosis, treatment and mortality of these patients, and the pathogens found in these patients. The mean age of the 136 patients was 67.9±14.2 years. Concurrent emphysematous infections of other organs were found in 21 patients (15.4%), with emphysematous pyelonephritis being the most common of these infections. The primary pathogen identified was Escherichia coli (54.4%). Patients were mainly treated by conservative management that included antibiotics (n=105; 77.2%). Ten of the 136 patients with EC died, yielding a mortality rate of 7.4%. Despite the relatively low mortality rate of EC compared with that of EP, a high degree of suspicion must be maintained to facilitate successful and conservative management.

Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy

Purpose: The aim of this study was to evaluate the true incidence of cervical artery dissections (CeADs) in trauma patients with an Injury Severity Score (ISS) of ≥16, since head-and-neck computed tomography angiogram (CTA) is not a compulsory component of whole-body trauma computed tomography (CT) protocols. Patients and methods: A total of 230 consecutive trauma patients with an ISS of ≥16 admitted to our Level I trauma center during a 24-month period were prospectively included. Standardized whole-body CT in a 256-detector row scanner included a head-and-neck CTA. Incidence, mortality, patient and trauma characteristics, and concomitant injuries were recorded and analyzed retrospectively in patients with carotid artery dissection (CAD) and vertebral artery dissection (VAD). Results: Of the 230 patients included, 6.5% had a CeAD, 5.2% had a CAD, and 1.7% had a VAD. One patient had both CAD and VAD. For both, CAD and VAD, mortality is 25%. One death was caused by fatal cerebral ischemia due to high-grade CAD. A total of 41.6% of the patients with traumatic CAD and 25% of the patients with VAD had neurological sequelae. Conclusion: Mandatory head-and-neck CTA yields higher CeAD incidence than reported before. We highly recommend the compulsory inclusion of a head-and-neck CTA to whole-body CT routines for severely injured patients.

Background: Artificial intelligence (AI) is often promoted as a potential solution for many challenges health care systems face worldwide. However, its implementation in clinical practice lags behind its technological development. Objective: This study aims to gain insights into the current state and prospects of AI technology from the stakeholders most directly involved in its adoption in the health care sector whose perspectives have received limited attention in research to date. Methods: For this purpose, the perspectives of AI researchers and health care IT professionals in North America and Western Europe were collected and compared for profession-specific and regional differences. In this preregistered, mixed methods, cross-sectional study, 23 experts were interviewed using a semistructured guide. Data from the interviews were analyzed using deductive and inductive qualitative methods for the thematic analysis along with topic modeling to identify latent topics. Results: Through our thematic analysis, four major categories emerged: (1) the current state of AI systems in health care, (2) the criteria and requirements for implementing AI systems in health care, (3) the challenges in implementing AI systems in health care, and (4) the prospects of the technology. Experts discussed the capabilities and limitations of current AI systems in health care in addition to their prevalence and regional differences. Several criteria and requirements deemed necessary for the successful implementation of AI systems were identified, including the technology’s performance and security, smooth system integration and human-AI interaction, costs, stakeholder involvement, and employee training. However, regulatory, logistical, and technical issues were identified as the most critical barriers to an effective technology implementation process. In the future, our experts predicted both various threats and many opportunities related to AI technology in the health care sector. Conclusions: Our work provides new insights into the current state, criteria, challenges, and outlook for implementing AI technology in health care from the perspective of AI researchers and IT professionals in North America and Western Europe. For the full potential of AI-enabled technologies to be exploited and for them to contribute to solving current health care challenges, critical implementation criteria must be met, and all groups involved in the process must work together.